INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION
WORMGO TABLETS

SCHEDULING STATUS:
S1

PROPRIETARY NAME
(and dosage form):

WORMGO TABLETS

COMPOSITION:
Each tablet contains 100 mg Mebendazole

PHARMACOLOGICAL CLASSIFICATION:
A.12 Anthelmintics, Bilharzia medicines, filaricides, etc.

PHARMACOLOGICAL ACTION:
Mebendazole is a broad-spectrum anthelmintic, and causes selective disappearance of cytoplasmic microtubules in the tegumental and intestinal cells of affected worms. Secretory substances accumulate in Golgi areas, secretion of acetylcholinesterase and uptake of glucose is impaired, and glycogen is depleted. These effects are not noted in host cells. Immobilization and death of the parasites occur slowly, and clearance from the gastrointestinal tract may not be complete until 3 days after treatment with mebendazole.

INDICATIONS:
Mebendazole is indicated for the treatment of single and mixed helminth infestations caused by:

	Ascariasis (roundworm)
	Ternidens deminutus
	Intestinal capillariasis
	Enterobiasis (pinworm)
	Trichuris trichiura (whipworm)
	Ancylostoma duodenale (hookworm)
	Necator americanus (hookworm)
	Strongyloides stercoralis (threadworm)
	Taenia spp (tapeworm)

These effects are not noted in host cells. Immobilization and death of the parasites occur slowly, and clearance from the gastrointestinal tract may not be complete until 3 days after treatment with mebendazole.
Mebendazole is indicated in the treatment of infestations by Moniliformis moniliformis.

CONTRA-INDICATIONS:
Mebendazole is teratogenic in experimental animals and should not be given during pregnancy and lactation.
Sensitivity to imidazoles.

DOSAGE AND DIRECTIONS FOR USE:
Fasting and purging is not required.
For infants under 2 years, see "Side-effects and special precautions".
For all worms excluding tapeworm and threadworm:
Dosage for adults and children:
One tablet twice daily (morning and evening) for three consecutive days.
If patient is not cured, 3 weeks after treatment a second course should be given.

For tapeworm:
Dosage for adults and children:
One tablet twice daily (morning and evening) for six consecutive days.
If the patient is not cured, 3 weeks after treatment, a second course should be given.

For threadworm:
Dosage for adults:
Two tablets twice daily for 3 consecutive days.
Dosage for children:
One tablet twice daily for 3 consecutive days.
This dosage should be repeated, if necessary, after 3 to 4 weeks.

For Capillaria philippinensis:
400 mg [4 tablets] should be given per day in divided doses for at least 20 days.
This medicine is not recommended for children under the age of 12 years with capillariases.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Nausea, vomiting, abdominal pain, and diarrhoea may occur.
Leucocyte counts should be done weekly for at least the first four weeks.
In higher dosages, Wormgo may cause vomiting, fever, transient neutropenia, alopecia, bone marrow suppression, raised hepatic enzymes and glomerulonephritis. Agranulocytosis has been reported.
Usage in children below 2 years is not well documented, and as there have been very exceptional reports of convulsions in this age group, mebendazole should only be given to very young children if their infections interfere significantly with nutritional status and physical development.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
See "Side-effects and special precautions."
Treatment is symptomatic and supportive.

IDENTIFICATION:
Wormgo Tablets: A pale peach tablet with bevelled edges, bisected on one side.

PRESENTATION:
Wormgo Tablets: Blister packs containing 6 tablets per unit carton and 300 tablets (50 x 6's) per unit carton.

STORAGE INSTRUCTIONS:
Store below 25°C.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
28/12/0281

NAME AND BUSINESS ADDRESS OF APPLICANT:
Pharmacare Limited
Building 12
Healthcare Park
Woodlands Drive
Woodmead
Sandton        2148

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
17/09/1993

A079
A&S PRINTERS

Updated on this site: April 2005
Source: Pharmaceutical Industry
SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2005